Nautilus Biotechnology, founded in 2016 by Seattle’s Sujal Patel and the San Francisco Bay Area’s Parag Mallick, is developing a device they say will identify and count 95% of the different types of proteins in a biological sample. The company also plans to measure key machinery inside cells with a level of detail that has never been done before.
The company said that the already existing device could measure up to 8% of the different types of proteins in blood samples. Nautilus Biotechnology says such protein measurements are unique to every person and change throughout people’s lives. This will not only help doctors identify more specific forms of disease but also help pharmaceutical companies find more precise drugs with fewer side effects.
Nautilus Biotechnology is one of many fast-growing companies in Washington’s life sciences sector. It’s an arena that has seen nearly $4 billion in transactions in the first half of 2021, ranging from private financings to acquisitions and initial public offerings. Life science companies have dominated the state’s IPOs in the first half of 2021. The company was backed by Jeff Bezos’ venture capital firm Bezos Expeditions, Microsoft co-founder Paul Allen’s Vulcan Capital, and Seattle-based Madrona Venture Group.